Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WHO reaffirms critical need for R&D for drug-resistant tuberculosis
WHO director-general Dr Margaret Chan said: "Addressing drug-resistant TB research is a top priority for WHO and for the world. "More than $800m per year is currently necessary
WHO director-general Dr Margaret Chan said: "Addressing drug-resistant TB research is a top priority for WHO and for the world. "More than $800m per year is currently necessary
The $30m funding round was led by Israel Biotech Fund (IBF) which identified the company, led the due diligence, and syndicated with leading US and Israeli biotechnology investors,
Advaxis’ proprietary technology generates innate immune stimulation, alongside potent and sustained T-cell responses. When combined with Sellas’ WT1 antigens, this has the potential to precisely direct an immune
If approved, Tafinlar + Mekinist will be the first targeted treatment available for patients with BRAF V600-positive NSCLC. Of the estimated 1.8 million new cases of lung cancer
A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology
In addition to demonstrating that PBI-4050 is safe and very well tolerated, an objective of this study was to seek early evidence of a clinical benefit with PBI-4050
Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug discovery and development scientists to conduct collaborative research aimed
The trial met its objectives and identified a Phase 2 dose regimen. Celiac disease is an immune-mediated gastrointestinal disease caused by dietary gluten predominantly in individuals who carry
This financing was led by Topspin Biotech Fund and a group of investors with Euclidean Capital, with participation from existing investors InterWest Partners, OrbiMed Advisors, and Osage University
AGS-v is intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability